China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients

Stress ulcers or stress-related mucosal disease (SRMD) is defined as "acute superficial inflammation lesions of the gastric mucosa induced when an individual is subject to abnormally elevated physiologic demands."[1] Studies have shown that SRMD occurred in 75%-100% ICU patients[1]. Gastrointestinal bleeding due to SRMD is an important complication in critically ill patients. The frequency of clinically important bleeding ranged from 5.3% to 33%.[2] The mortality in ICU patients with stress related bleeding approaches 50%, which is much higher than the patients without bleeding (9%). [3] In 1999, the American Society of Health-System Pharmacists (ASHP) published guidelines on the use of stress ulcer prophylaxis in medical, surgical, respiratory, and pediatric ICU patients [2]. PPIs and H2RA are widely used in China current clinical practice for the prevention of stress ulcer bleeding. However, there is no epidemiology data to show the risk factors for stress ulcer bleeding and the bleeding rate of Chinese neurosurgical critically ill patients who are usually suffering from brain trauma, cerebral haemorrhage or brain tumour operation. Information is needed to know about the characteristics in Chinese critically ill neurosurgical patients.

Objectives of this Non-Interventional Study Primary

1. Primary objective: To estimate the overall incidence of upper gastrointestinal (GI) bleeding in critically ill neurosurgical patients in China. 2. Main secondary objective

* To estimate the incidence of upper GI bleeding with clinically significant complications in critically ill neurosurgical patients in China. * To estimate the incidence of any overt upper GI bleeding without clinically significant complications in critically ill neurosurgical patients in China. * To assess time to upper GI bleeding after a cerebral lesion. * To investigate potential risk factors associated with upper GI bleeding, and assess how common certain risk factors occurred in upper GI bleeding patients. * To assess the overall incidence of upper GI bleeding in critically ill patients by different risk factors for upper GI bleeding. * To investigate the drugs, the route of administration, the doses and the duration commonly used for stress ulcer prophylaxis. * To investigate the proportion of ICU patients with nasogastric tube, and the duration of nasogastric tube.

(ICU: Intensive care unit PPIs: Proton pump inhibitors H2RA: H2 receptor antagonist)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stress Ulcers Digestive System Diseases Duodenal Diseases Duodenal Ulcer Gastrointestinal Diseases Intestinal Diseases Peptic Ulcer Stomach Diseases Stress-related Mucosal Disease (SRMD)

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Beijing, Beijing Municipality, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments. Those whose Glasgow Coma Scale (GCS) ≤10[4] within 24 hours of lesion/admission will be defined as critically ill patients. Three kinds of cases will be included: brain trauma critically ill patients, cerebral haemorrhage critically ill patients or postoperative brain tumour critically ill patients.

Exclusion criteria

If participating in any clinical trial, the subject cannot take part in this study. Subjects are ineligible if they have below conditions:

Those who were likely to swallow blood (for example, those with severe facial trauma or epistaxis;
Patients with previous total gastrectomy;
Known upper GI lesions that might bleed (e.g., varices, polyps, tumours, etc);
Evidence of active GI bleeding including oesophageal and gastric variceal bleeding, Peptic Ulcer Disease (PUD)

Treatment and study plan

Primary outcomes

The primary variable is the overall incidence of upper GI bleeding in critically ill neurosurgical patients

Time frame: during the first 14 days (up to 14 days) after the cerebral lesion (trauma, haemorrhage or postoperative).

Secondary outcomes

The incidence of upper GI bleeding with clinically significant complications in critically ill neurosurgical patients

Time frame: during the first 14 days (up to 14 days) after the cerebral lesion (trauma, haemorrhage or postoperative).

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: SUP

Important dates

Study start: 2015
Primary completion: 2015
Study completion: 2015
First posted: Dec 15, 2014
Registry last updated: Feb 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed